Asia Pacific Biosimilars Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Asia Pacific Biosimilars Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Asia Pacific Biosimilars Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Asia Pacific Biosimilars Market Regional Analysis

6.2 Asia Pacific Biosimilars Market Revenue 2020-2028 (US$ Million)

6.3 Asia Pacific Biosimilars Market Forecast Analysis

7. Asia Pacific Biosimilars Market Analysis – by Disease Indication

7.1 Cancer

7.1.1 Overview
7.1.2 Cancer: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.2 Diabetes

7.2.1 Overview
7.2.2 Diabetes: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.3 Autoimmune Diseases

7.3.1 Overview
7.3.2 Autoimmune Diseases: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

7.4 Other Diseases

7.4.1 Overview
7.4.2 Other Diseases: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

8. Asia Pacific Biosimilars Market Analysis – by Drug Class

8.1 Granulocyte Colony-Stimulating Factors

8.1.1 Overview
8.1.2 Granulocyte Colony-Stimulating Factors: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

8.2 Human Growth Hormone

8.2.1 Overview
8.2.2 Human Growth Hormone: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

8.3 Insulin

8.3.1 Overview
8.3.2 Insulin: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

8.4 TNF Blockers & Monoclonal Antibodies

8.4.1 Overview
8.4.2 TNF Blockers & Monoclonal Antibodies: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

8.5 Erythropoietin-Stimulating Agents

8.5.1 Overview
8.5.2 Erythropoietin-Stimulating Agents: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

9. Asia Pacific Biosimilars Market Analysis – by Route of Administration

9.1 Intravenous

9.1.1 Overview
9.1.2 Intravenous: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

9.2 Subcutaneous

9.2.1 Overview
9.2.2 Subcutaneous: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

10. Asia Pacific Biosimilars Market Analysis – by End User

10.1 Hospitals

10.1.1 Overview
10.1.2 Hospitals: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

10.2 Speciality Clinics

10.2.1 Overview
10.2.2 Speciality Clinics: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

10.3 Homecare

10.3.1 Overview
10.3.2 Homecare: Asia Pacific Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)

11. Asia Pacific Biosimilars Market – Asia-Pacific Analysis

11.1 Overview

11.2 Asia-Pacific

11.2.1 Asia Pacific Biosimilars Market Breakdown, by Key Country, 2023 and 2028 (%)
11.2.1.1 Asia Pacific Biosimilars Market – Revenue and Forecast Analysis – by Country
11.2.1.1 China: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.1.1 China: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
11.2.1.1.2 China: Asia Pacific Biosimilars Market Breakdown, by Drug Class
11.2.1.1.3 China: Asia Pacific Biosimilars Market Breakdown, by Route of Administration
11.2.1.1.4 China: Asia Pacific Biosimilars Market Breakdown, by End User

11.2.1.2 India: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.2.1 India: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
11.2.1.2.2 India: Asia Pacific Biosimilars Market Breakdown, by Drug Class
11.2.1.2.3 India: Asia Pacific Biosimilars Market Breakdown, by Route of Administration
11.2.1.2.4 India: Asia Pacific Biosimilars Market Breakdown, by End User

11.2.1.3 Japan: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.3.1 Japan: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
11.2.1.3.2 Japan: Asia Pacific Biosimilars Market Breakdown, by Drug Class
11.2.1.3.3 Japan: Asia Pacific Biosimilars Market Breakdown, by Route of Administration
11.2.1.3.4 Japan: Asia Pacific Biosimilars Market Breakdown, by End User

11.2.1.4 Australia: Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.4.1 Australia: Asia Pacific Biosimilars Market Breakdown, by Disease Indication
11.2.1.4.2 Australia: Asia Pacific Biosimilars Market Breakdown, by Drug Class
11.2.1.4.3 Australia: Asia Pacific Biosimilars Market Breakdown, by Route of Administration
11.2.1.4.4 Australia: Asia Pacific Biosimilars Market Breakdown, by End User

11.2.1.5 Rest of Asia-Pacific : Asia Pacific Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by Disease Indication
11.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by Drug Class
11.2.1.5.3 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by Route of Administration
11.2.1.5.4 Rest of Asia-Pacific : Asia Pacific Biosimilars Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Amgen Inc

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Sanofi SA

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Biocon Ltd

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Eli Lilly and Co

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Sandoz AG

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Teva Pharmaceutical Industries Ltd

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Pfizer Inc

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 Dr. Reddy's Laboratories Ltd

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 Celltrion Inc

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Samsung Bioepis Co Ltd

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Asia Pacific Biosimilars Market